TPBG
AVXL icon

Turning Point Benefit Group’s Anavex Life Sciences AVXL Stock Holding History

Turning Point Benefit Group’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-150
Closed -$534 – 154
2025
Q4 		$534 Buy
+150
New +$919 ﹤0.01% 631

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Turning Point Benefit Group's AVXL Position: Q1 2026 in Review

Turning Point Benefit Group sold out of Anavex Life Sciences (AVXL) in Q1 2026, closing a stake of 150 shares — an estimated $534 sold.

Turning Point Benefit Group first reported a position in AVXL in Q4 2025 and held it in 1 quarter. The position peaked at $534 in Q4 2025. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

  • Turning Point Benefit Group reported no remaining Anavex Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Turning Point Benefit Group sold 150 Anavex Life Sciences shares in Q1 2026, an estimated $534.
  • Turning Point Benefit Group first reported a position in Anavex Life Sciences in Q4 2025 and held it in 1 quarter.
  • Turning Point Benefit Group's Anavex Life Sciences position peaked at $534 in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on Turning Point Benefit Group's 13F filing for Q1 2026, filed 12 May 2026.